Claims
- 1. A system for delivery of an antiinfective agent comprising:
a) a pharmaceutical formulation comprising a particle comprising an antiinfective agent directed to prevention and treatment of intracellular infections in the lung caused by an infective agent, the pharmaceutical formulation comprising particles with a diameter of between approximately 0.01 microns and approximately 2.0 microns and, b) an inhalation delivery device.
- 2. The system of claim 1 wherein the particles have a diameter of between approximately 0.01 microns and approximately 1.0 micron.
- 3. The system of claim 1 wherein the particles have a diameter of between approximately 0.01 microns and approximately 0.5 microns.
- 4. The system of claim 1 wherein the particles have a diameter of between approximately 0.02 microns and approximately 0.5 microns.
- 5. The system of claim 1, wherein the infective agent is a bacteria.
- 6. The system of claim 5, wherein the bacteria is selected from Bacillus anthracis, Listeria monocytogenes, Staphylococcus aureus, Salmenellolosis, Pseudomonas aeruginosa, Yersina pestis, Mycobacterium leprae, M. africanum, M. asiaticum, M. avium-intracellulare, M. chelonei subsp. abscessus, M. fallax, M. fortuitum, M. kansasii, M. leprae, M. malmoense, M. shimoidei, M. simiae, M. szulgai, M. xenopi, M. tuberculosis, Brucella melitensis, Brucella suis, Brucella abortus, Brucella canis, Legionella pneumonophilia, Francisella tularensi, pneumocystis carinii and mycoplasma.
- 7. The system of claim 6 wherein the bacteria is Bacillus anthracis.
- 8. The system of claim 6 wherein the bacteria is Mycobacterium leprae.
- 9. The system of claim 6 wherein the bacteria is M.tuberculosisI.
- 10. The system of claim 1, wherein the infective agent is a virus.
- 11. The system of claim 1, wherein the virus is selected from hantavirus, respiratory syncytial virus, influenza, and viral pneumonia.
- 12. The system of claim 1, wherein the pharmaceutical formulation comprises the antiinfective agent in particle form.
- 13. The system of claim 1, wherein the pharmaceutical formulation comprises a mixture of the antiinfective agent and one or more excipients.
- 14. The system of claim 13, wherein the one or more excipients are selected from sugars, salts and polymers.
- 15. The system of claim 1, wherein the pharmaceutical formulation comprises a non-covalent modification of the antiinfective agent.
- 16. The system of claim 7, wherein the non-covalent modification of the antiinfective agent is a salt.
- 17. The system of claim 8, wherein the salt is selected from the sodium, potassium, lithium, sulfate, citrate, phosphate, calcium, magnesium or iron salt of the antiinfective agent.
- 18. The system of claim 1, wherein the pharmaceutical formulation comprises the ant linfective agent and one or more lipids, the antiinfective agent and the one or more lipids being formulated as a lipid mixture.
- 19. The system of claim 10, wherein the antiinfective agent to lipid ratio is from 10:1 to 1:1000 by weight.
- 20. The system of claim 1, wherein the pharmaceutical formulation comprises the antiinfective agent and a mixture of phospholipids.
- 21. The system of claim 12, wherein the mixture of phospholipids comprises one or more phospholipids selected from the group consisting of phosphatidylcholines, phosphatidylglycerols, phosphatidylserines, phosphotidylinositols, phosphatidylethanolamines, sphingomyelins, ceramides, and steroids.
- 22. The system of claim 12, wherein the pharmaceutical formulation further comprises a mixture of one or more steroids.
- 23. The system of claim 1, wherein the pharmaceutical formulation comprises the antiinfective agent and a lipid, the antiinfective agent and the lipid being formulated as a lipid complex.
- 24. The system of claim 1, wherein the pharmaceutical formulation comprises a liposome.
- 25. The system of claim 16, wherein the liposome is a multilamellar vesicle.
- 26. The system of claim 16, wherein the liposome is a small unilamellar vesicle.
- 27. The system of claim 1, wherein the pharmaceutical formulation comprises a lipid complex with a diameter of from approximately 0.01 microns to approximately 6.0 microns.
- 28. The system of claim 27, wherein the pharmaceutical formulation comprises a lipid complex with a diameter of from approximately 0.01 microns to approximately 0.5 microns.
- 29. The system of claim 1, wherein the pharmaceutical formulation comprises a lipid clathrate with a diameter of from approximately 0.01 microns to approximately 6.0 microns.
- 30. The system of claim 29, wherein the pharmaceutical formulation comprises a lipid clathrate with a diameter of from approximately 0.01 microns to approximately 0.5 microns.
- 31. The system of claim 1, wherein the pharmaceutical formulation comprises a proliposome.
- 32. The system of claim 1, wherein the pharmaceutical formulation comprises a polymer formulation of the antiinfective agent.
- 33. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a quinolone.
- 34. The system of claim 33 wherein the quinolone is ciprofloxicin, norfloxacin, ofloxacin, moxifloxacin or levofloxacin.
- 35. The system of claim 34 wherein the quinolone is ciprofloxacin.
- 36. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a tetracycline.
- 37. The system of claim 36 wherein the tetracycline is doxycycline, minocycline, oxytetracycline, demeclocycline, or methacycline.
- 38. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a penicillin.
- 39. The system of claim 38 wherein the antiinfective agent additionally comprises a beta lactamase inhibitor.
- 40. The system of claim 38 wherein the penicillin is penicillin G, penicillin V, a penicillinase-resistant penicillin, an isoxazolyl penicillin, an amino penicillin, or a ureidopenicillin.
- 41. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a cephalosporin.
- 42. The system of claim 41, wherein the antiinfective agent additionally includes a beta lactamase inhibitor.
- 43. The system of claim 42 wherein the beta lactamase inhibitor is clavulanate, sulfactam, or tazobactam.
- 44. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a macrolide.
- 45. The system of claim 44, wherein the macrolide is erythromycin, rifampin, clarithromycin, dirithromycin or troleandomycin
- 46. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is an aminoglycoside.
- 47. The system of claim 46, wherein the aminoglycoside is amikacin, streptomycin, gentamycin, tobramycin, netilmicin, or kanamycin.
- 48. The system of claim 47, wherein the aminoglycoside is amikacin.
- 49. The system of claim 47, wherein the aminoglycoside is tobramycin.
- 50. The system of claim 47 wherein the aminoglycoside is gentamycin.
- 51. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a glycopeptide.
- 52. The system of claim 51, wherein the glycopeptide is vancomycin or teicoplanin.
- 53. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a cephamycin.
- 54. The system of claim 53, wherein the cephamycin is cefoxitin or cefotetan.
- 55. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a monobactam.
- 56. The system of claim 55 wherein the monobactam is aztreonam.
- 57. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a carbapapenem.
- 58. The system of claim 57 wherein the carbapapenem is imipenem or meropenem.
- 59. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a lincosamide.
- 60. The system of claim 59 wherein the lincosamide is lincomycin or clindamycin.
- 61. The system of claim 1, wherein the ant linfective agent directed to treatment of intracellular infection is an oxazolidinone.
- 62. The system of claim 61 wherein the oxazolidinone is linezolid.
- 63. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is a streptogranin.
- 64. The system of claim 63 wherein the streptogranin is dalfopristin or quinupristin.
- 65. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is chloramphenicol.
- 66. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is trimethoprine.
- 67. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is sulfamethoxazole.
- 68. The system of claim 1, wherein the antiinfective agent directed to treatment of intracellular infection is nitrofurantoin.
- 69. The system of claim 1, wherein the inhalation delivery device is an aerosolizer.
- 70. The system of claim 1, wherein the inhalation delivery device is a nebulizer.
- 71. The system of claim 1, wherein the inhalation delivery device is a powder administering device.
- 72. The system of claim 1, wherein the intracellular infection is Bacillus antracis and the antiinfective agent is ciprofloxacin.
- 73. The system of claim 1, wherein the intracellular infection is M.tuberculosis and the antiinfective agent is isoniazid.
- 74. A method for treatment of intracellular infection comprising:
a) providing a pharmaceutical formulation of a particle comprising an antiinfective agent, the antiinfective agent being directed to treatment of intracellular infections in the lung, the pharmaceutical formulation comprising particles with a diameter of between approximately 0.01 microns and approximately 2.0 microns; b) providing an inhalation delivery device; and, c) delivering the composition to the respiratory tract by inhalation.
- 75. The method of claim 74, wherein the particles have a diameter of between approximately 0.01 microns and approximately 1.0 microns.
- 76. The method of claim 74, wherein the particles have a diameter of between approximately 0.01 microns and approximately 0.5 microns.
- 77. The method of claim 74, wherein the infective agent is a bacteria.
- 78. The method of claim 77 wherein the bacteria is selected from Bacillus anthracis, Listeria monocytogenes, Staphylococcus aureus, Salmenellolosis, Pseudomonas aeruginosa, Yersina pestis, Mycobacterium leprae, M. africanum, M. asiaticum, M. avium-intracellulare, M. chelonei subsp. abscessus, M. fallax, M. fortuitum, M. kansasii, M. leprae, M. malmoense, M. shimoidei, M. simiae, M. szulgai, M. xenopi, M. tuberculosis, Brucella melitensis, Brucella suis, Brucella abortus, Brucella canis, Legionella pneumonophilia, Francisella tularensis, pneumocystis carinii or mycoplasma.
- 79. The method of claim 78 wherein the bacteria is Bacillus anthracis.
- 80. The method of claim 78 wherein the bacteria is Mycobacterium leprae.
- 81. The method of claim 78 wherein the bacteria is M. tuberculosis.
- 82. The method of claim 78 wherein the bacteria is Legionella pneumonophilia.
- 83. The method of claim 74 wherein the infective agent is a virus.
- 84. The method of claim 83 wherein the virus is selected from from hantavirus, respiratory syncytial virus, influenza, and viral pneumonia.
- 85. The method of claim 74 wherein the antiinfective agent is in particle form.
- 86. The method of claim 74 wherein the inhalation delivery device comprises an aerosolizer.
- 87. The method of claim 74 wherein the inhalation delivery device comprises a nebulizer.
- 88. The method of claim 74 wherein the inhalation delivery device comprises a dry powder inhalator.
- 89. The method of claim 74 wherein the antiinfective agent is formulated as a lipid mixture.
- 90. The method of claim 74 wherein the ant linfective agent is formulated as a lipid complex.
- 91. The method of claim 74 wherein the antiinfective agent is incorporated into a liposome.
- 92. The method of claim 74, wherein the pharmaceutical formulation comprises a lipid complex with a diameter of from approximately 0.01 microns to approximately 0.5 microns.
- 93. The method of claim 74, wherein the pharmaceutical formulation comprises a lipid clathrate with a diameter of from approximately 0.01 microns to approximately 0.5 microns.
- 94. The method of claim 74, wherein the pharmaceutical formulation comprises a proliposome.
Parent Case Info
[0001] The present application claims the benefit of the priority of U.S. Provisional Patent Application No. 60/361,809 filed Mar. 5, 2002, the disclosure of which is hereby incorporated by reference as if fully set forth herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60361809 |
Mar 2002 |
US |